This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Constellation’s merger remedy lowers US antitrust hurdle for Calpine buy

By Ilana Kowarski ( February 5, 2025, 18:09 GMT | Comment) -- Power companies Constellation Energy and Calpine have pitched a divestiture that's strategically aimed at the most obvious and significant antitrust concerns for their planned merger, which is likely to elicit tough US government scrutiny. It’s possible the Constellation-Calpine remedy proposal or a slightly more generous one would satisfy regulators, but even if they deem the remedy offer to be insufficient, the divestiture provides a solid foundation for negotiations between merging parties and government officials — boosting the deal's odds.Power companies Constellation Energy and Calpine have pitched a divestiture that's strategically aimed at the most obvious and significant antitrust concerns for their planned merger, which would fuse two major players in the US electricity industry in a deal likely to elicit tough US government scrutiny....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login